Sagittarius Life Science Corp (TPEX:3205)
46.95
+0.15 (0.32%)
Oct 20, 2026, 1:30 PM CST
Sagittarius Life Science Revenue
Sagittarius Life Science had revenue of 188.12M TWD in the quarter ending June 30, 2026, with 66.94% growth. This brings the company's total for the last twelve months to 467.69M, up 4.86% year-over-year. In the year 2025, Sagittarius Life Science had annual revenue of 346.08M, down -26.01%. That makes Sagittarius Life Science the 35,597th largest company in the world by revenue and 1,855th in Taiwan.
Revenue (ttm)
467.69M
Revenue Growth
+4.86%
P/S Ratio
6.78
Revenue / Employee
4.18M
Employees
112
Market Cap
3.17B
Revenue by Geography
- Taiwan 338.53M 97.8%
- Asia 7.55M 2.2%
Fiscal year ended Dec 31, 2025 See the full Sagittarius Life Science breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 346.08M | -121.67M | -26.01% |
| Dec 31, 2024 | 467.75M | 27.29M | 6.20% |
| Dec 31, 2023 | 440.46M | -88.61M | -16.75% |
| Dec 31, 2022 | 529.07M | -58.55M | -9.96% |
| Dec 31, 2021 | 587.61M | 29.43M | 5.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SYN-TECH Chem. & Pharm. | 1.27B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| BioGend Therapeutics | 236.58M |
| 3D Global Biotech | 159.19M |
| Pharmosa Biopharm | 53.38M |
| Formosa Pharmaceuticals | 52.59M |
| Shine-On BioMedical | 50.62M |
| Intech Biopharm | 48.55M |